Healthcare provider profile · identity verified

Michael J. Mentakis, MD

Internal Medicine · U SADDLE RIV, NJ · NPI 1811988033

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Trazodone Hcl	Trazodone Hcl	300	59
Atorvastatin Calcium	Atorvastatin Calcium	286	70
Eliquis	Apixaban	272	28
Gabapentin	Gabapentin	185	38
Tamsulosin Hcl	Tamsulosin Hcl	171	36
Amlodipine Besylate	Amlodipine Besylate	161	38
Levothyroxine Sodium	Levothyroxine Sodium	154	34
Mirtazapine	Mirtazapine	145	26
Quetiapine Fumarate	Quetiapine Fumarate	139	26
Divalproex Sodium	Divalproex Sodium	131	19
Omeprazole	Omeprazole	131	33
Lisinopril	Lisinopril	129	36
Metformin Hcl	Metformin Hcl	127	29
Sertraline Hcl	Sertraline Hcl	120	26
Olanzapine	Olanzapine	106	18
Risperidone	Risperidone	104	16
Escitalopram Oxalate	Escitalopram Oxalate	97	14
Metoprolol Succinate	Metoprolol Succinate	96	25
Furosemide	Furosemide	83	17
Metoprolol Tartrate	Metoprolol Tartrate	65	16
Carvedilol	Carvedilol	61	18
Torsemide	Torsemide	58	13
Famotidine	Famotidine	57	15
Lidocaine	Lidocaine	57	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	55	20
Ibuprofen	Ibuprofen	54	suppressed
Finasteride	Finasteride	52	11
Fluoxetine Hcl	Fluoxetine Hcl	52	12
Rosuvastatin Calcium	Rosuvastatin Calcium	46	14
Memantine Hcl	Memantine Hcl	45	suppressed
Simvastatin	Simvastatin	45	12
Montelukast Sodium	Montelukast Sodium	44	suppressed
Donepezil Hcl	Donepezil Hcl	43	suppressed
Losartan Potassium	Losartan Potassium	43	16
Tradjenta	Linagliptin	43	suppressed
Clozapine	Clozapine	42	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	42	15
Midodrine Hcl	Midodrine Hcl	40	suppressed
Levetiracetam	Levetiracetam	38	suppressed
Baclofen	Baclofen	37	suppressed
Clopidogrel	Clopidogrel Bisulfate	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	36	suppressed
Xarelto	Rivaroxaban	36	suppressed
Duloxetine Hcl	Duloxetine Hcl	34	suppressed
Fluticasone Propionate	Fluticasone Propionate	34	15
Farxiga	Dapagliflozin Propanediol	33	suppressed
Jardiance	Empagliflozin	33	suppressed
Warfarin Sodium	Warfarin Sodium	30	suppressed
Spironolactone	Spironolactone	28	suppressed
Folic Acid	Folic Acid	27	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Latanoprost	Latanoprost	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Diclofenac Sodium	Diclofenac Sodium	24	11
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Oxycodone Hcl	Oxycodone Hcl	24	12
Lactulose	Lactulose	23	suppressed
Nyamyc	Nystatin	23	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	11
Topiramate	Topiramate	22	suppressed
Bupropion Hcl	Bupropion Hcl	21	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Aripiprazole	Aripiprazole	20	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	20	suppressed
Incruse Ellipta	Umeclidinium Bromide	20	suppressed
Betamethasone Valerate	Betamethasone Valerate	19	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	19	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	18	suppressed
Novolog	Insulin Aspart	18	suppressed
Nystatin	Nystatin	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Benztropine Mesylate	Benztropine Mesylate	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Labetalol Hcl	Labetalol Hcl	17	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Airsupra	Albuterol Sulfate/Budesonide	15	suppressed
Allopurinol	Allopurinol	15	suppressed
Cephalexin	Cephalexin	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Prazosin Hcl	Prazosin Hcl	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Prednisone	Prednisone	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Acetazolamide Er	Acetazolamide	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Humalog	Insulin Lispro	12	suppressed
Lithium Carbonate	Lithium Carbonate	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Acamprosate Calcium	Acamprosate Calcium	11	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Ramelteon	Ramelteon	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error